Trypanosoma brucei gambiense group 1 is the major causative agent of the Gambian human African trypanosomiasis (HAT). Accurate diagnosis of Gambian HAT is still challenged by lack of precise diagnostic methods, low and fluctuating parasitemia, and generally poor services in the areas of endemicity. In this study, we designed a rapid loop-mediated isothermal amplification (LAMP) test for T. b. gambiense based on the 3 end of the T. b. gambiense-specific glycoprotein (TgsGP) gene. The test is specific and amplifies DNA from T. b. gambiense isolates and clinical samples at 62°C within 40 min using a normal water bath. The analytical sensitivity of the TgsGP LAMP was equivalent to 10 trypanosomes/ml using purified DNA and ϳ1 trypanosome/ml using supernatant prepared from boiled blood, while those of classical PCR tests ranged from 10 to 10 3 trypanosomes/ml. There was 100% agreement in the detection of the LAMP product by real-time gel electrophoresis and the DNA-intercalating dye SYBR green I. The LAMP amplicons were unequivocally confirmed through sequencing and analysis of melting curves. The assay was able to amplify parasite DNA from native cerebrospinal fluid (CSF) and double-centrifuged supernatant prepared from boiled buffy coat and bone marrow aspirate. The robustness, superior sensitivity, and ability to inspect results visually through color change indicate the potential of TgsGP LAMP as a future point-of-care test.
Trypanosoma brucei gambiense is the causative agent of the Gambian form of human African trypanosomiasis (HAT) in sub-Saharan Africa and is responsible for over 90% of all HAT cases (7) . The Gambian HAT is endemic to rural areas of West and Central Africa, where deterioration of control activities, severe disruptions of health services, and population movements into high-risk areas have led to resurgence of the disease (47) . T. b. gambiense infection is characterized by low parasitemia with no specific clinical symptoms (15) , especially during the early stage, when the trypanosomes are confined to the hemolymphatic system. This has limited the use of standard diagnostic techniques, with an estimated 20 to 30% of patients being undiagnosed (42) . The serological test-card agglutination test for trypanosomiasis (CATT)-for T. b. gambiense (24) is widely used; however, the test has varying sensitivities (46) and cannot decisively differentiate between active and cured cases (19) . On the molecular side, several PCR tests have been developed (6, 30, 41) , but issues of sensitivity and reproducibility (44) and the requirement for high-precision instrumentation have limited their use.
Early and accurate diagnosis of Gambian HAT is essential, since the drugs used for treatment, particularly those for the late stage, can cause unacceptably severe side effects. The first stage of disease is treated with pentamidine, while the second stage is treated with melarsoprol, which is associated with encephalopathy in about 10% of treated patients (39, 49) .
Eflornithine is an alternative drug for the second stage of Gambian HAT but is expensive and difficult to administer (48) . The latest advance in treatment has been a combination of eflornithine and nifurtimox (40) ; this brings with it reduction of the treatment duration, as well as the number of eflornithine infusions, to the relief of nursing staff attending to the patients. This complexity in the treatment regime calls for a diagnostic test(s) that is accurate and that minimizes false positives to reduce overtreatment and exposure of patients to expensive and potentially toxic drugs whose efficacy may not be guaranteed.
In recent years, a DNA amplification platform called loopmediated isothermal amplification (LAMP) has been developed (36) . The technique has been used to develop LAMP tests specific for the subgenus Trypanozoon (18, 34, 45) and Trypanosoma brucei rhodesiense (35) , but so far, there is no LAMP test for T. b. gambiense. The major advantages of LAMP include (i) rapidity and the use of six to eight primers providing high specificity; (ii) ability of the technique to amplify target DNA from partially processed template; (iii) requirement for only a simple heating device, such as a water bath; and (iv) results that can be inspected visually through the use of varied detection formats, such as turbidity (28) , fluorescent dye (5), probes (1, 27) , lateral-flow dipstick (LFD) format (31) , and microfluidic chips (13) . LAMP has attracted much interest as an easily applicable yet highly sensitive molecular tool with great potential for diagnosis in resource-poor rural settings, where HAT typically occurs. This is demonstrated by the large number of publications on the technique (26) .
The molecular characterization of human-infective trypanosomes indicates that the majority of Gambian HAT cases are caused by a genetically homogeneous group, group 1 T. b.
gambiense (12, 17, 37) , with group 2 T. b. gambiense accounting for an insignificant percentage (25) . In addition, studies have identified a T. b. gambiense-specific glycoprotein (TgsGP) gene (2) that is specific to group 1 T. b. gambiense and absent in isolates from group 2 (14) . The 3Ј end of the TgsGP gene has been used to develop the only reliable PCR tests for T. b. gambiense (41) . In this study, we designed a rapid and sensitive LAMP test based on the 3Ј end of the TgsGP gene and evaluated it using Trypanozoon isolates and clinical samples from HAT patients with a view to obtaining data for a more comprehensive field study.
MATERIALS AND METHODS
Ethical clearance. Institutional ethical clearance for the collection of human samples in Uganda was obtained from the Uganda National Council of Science and Technology (UNCST), Kampala, Uganda, as reported previously (34) , and the use of samples from a HAT patient diagnosed in Australia was approved by Royal Perth Hospital, Western Australia, Australia, through Christopher Heath.
Reference DNA. Well-characterized T. b. gambiense DNA samples were used in this study, as shown in Table 1 . The DNA was prepared either using a Qiagen DNA extraction kit (Qiagen, Victoria, Australia) or by the published method (43) . The samples were chosen to ensure wide geographical representation. DNA from other trypanosome species, tsetse fly, bovine, human, and Plasmodium falciparum were included to check the test specificity.
Clinical samples. Ten DNA samples prepared from blood and cerebrospinal fluid (CSF) from confirmed T. b. gambiense patients in Uganda, as previously reported (35) , were used. The OM series samples were purified using a Gentra (Minneapolis, MN) DNA purification kit. Additionally, a variety of samples (the RPH series) from a T. b. gambiense patient diagnosed in Australia were also included ( Table 2 ). The samples were prepared as follows. First, the buffy coat (BC) was prepared from a pool of 10 heparinized blood capillaries and made up to 210 l with ultrapure-grade water; then, equal amounts (210 l) of the BC, the bone marrow aspirate (BMA), and CSF were divided into three equal portions for (i) direct use, (ii) extraction of DNA using the commercial kit, and (iii) supernatant processing as described previously (34) . To reduce the chances of false positives (33), the collected supernatant was double centrifuged at 14,000 rpm for 5 min. The prepared samples were then stored at Ϫ80°C until they were needed. The template for a 50-l reaction mixture was 4 to 5 l for supernatant and 1 to 2 l for DNA, direct BC, BMA, or CSF samples ( Table 2) .
Design of LAMP primers. A total of five primer sets recognizing six distinct sections of TgsGP (accession number AJ277951) were designed using Primer Explorer version 3 software (http://primerexplorer.jp/lamp3.0.0/index.html). They included forward and backward outer primers (F3 and B3) and forward and backward inner primers (FIP and BIP) ( Table 3) . Additionally, two loop primers, loop forward (LF) and loop backward (LB), were manually designed for each set. The 3Ј end of the TgsGP gene was chosen for amplification because of its reported specificity to T. b. gambiense (14, 41) . Primer specificity was checked with the basic local alignment search tool (BLAST) against human DNA and other human-infectious pathogens. The primer sets were analyzed with "mustdetect samples," i.e., T. b. gambiense isolates, and "must-not-detect samples," i.e., T. b. rhodesiense, Trypanosoma brucei brucei, and Trypanosoma evansi ( Table 1) . The sets of primers that passed these criteria were then analyzed using a 10-fold serial dilution of T. b. gambiense DNA from isolate PT41 under the standard LAMP conditions (36) . The most sensitive primer set (Table 3 ) was then chosen for further analysis. LAMP reactions. To improve the sensitivity of TgsGP LAMP primers, four reaction mixture components (magnesium sulfate, FIP/BIP primers, deoxynucleoside triphosphates [dNTPs] , and betaine) were subjected to rigorous optimization using the modified Taguchi method, followed by regression analysis to determine the concentration optima for each reaction mixture component (9) . Briefly the forward inner primer (FIP) and backward inner primer (BIP) concentrations were varied from 20 to 80 pmol, dNTPs (Promega, NSW, Australia) from 1 to 4 mM, betaine (Sigma-Aldrich, St. Louis, MO) from 0.5 to 2.0 M, and magnesium sulfate (New England BioLabs, MA) from 0 to 6 mM. The 1ϫ ThermoPol reaction buffer contained 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , and 0.1% Triton X-100. The Bst DNA polymerase (large fragment; New England BioLabs, MA) was at 1 l (8 units), while SYTO-9 fluorescent dye at 3.0 M (Molecular Probes, OR) was added for each real-time reaction. The template was ϳ1 ng of purified trypanosome DNA from the T. b. gambiense isolate PT41. The LAMP reaction was performed for 30 to 60 min at 62°C using the Rotor Gene 6000 (Qiagen, Victoria, Australia), and data were acquired on the HRM channel (460 to 510 nm), followed by inactivation of the reaction at 80°C for 4 min. After the optimized conditions were determined, they were compared with the standard LAMP conditions, followed by trials using a normal water bath that maintained the temperature at ϳ62 to 63°C. For comparison purposes, the mobile genetic element (RIME) LAMP (34) specific for the subgenus Trypanozoon was carried out.
Detection and confirmation of LAMP products. The formation of LAMP product was first monitored in real time through fluorescence of Syto-9 dye, after which the product was divided into two equal portions of ϳ10 l each. One portion was analyzed using electrophoresis in 2.0% agarose gels stained with SYBR safe DNA gel stain and the other by visual inspection after the addition of a 1/10 dilution of SYBR green I. Two approaches were used to confirm that the TgsGP LAMP test amplified the correct target, namely, (i) the acquisition of melting curves using 1°C steps, with a hold of 30 s, from 62°C to 96°C and (ii) 
c,e
c,e TgsGP-F3  GTTCGGAGAGCTCAGACAG  19  150  TgsGP gene  TgsGP-B3  CCAACCGTTCCCAGTGTTG  19  TgsGP-FIP  TTGCTCCTTATCGCCGCCAGGCAAGAGCACAAAACCACAG  40  TgsGP-BIP  TGACGGGGACAACGGCTATCTATTTAACGCAGACACCGCC  40  TgsGP-LF  CCGCCCTGATCCCGCCTG  18  TgsGP-LB  GCAACTGCACAGGAACGGCG  20 a Length between F2 and B2c.
through cloning of the uppermost single band into a Topo-TA vector, transformation in Escherichia coli, and sequencing. The resulting sequence was manually compared with the expected target sequence. Sensitivity of TgsGP LAMP and PCR. A 10-fold serial dilution of ϳ100 ng of T. b. gambiense isolate PT41 DNA was used. Second, DNA and supernatant were prepared from archived mouse blood that had been mixed with T. b. gambiense. Briefly, cultured T. b. gambiense parasites were mixed with mouse blood, adjusted to achieve approximately 1.0 ϫ 10 6 trypanosomes/ml, and divided into two portions. One portion was used for DNA extraction using the Qiagen kit, and the other was boiled for supernatant as described previously (34). Tenfold serial dilutions were then prepared from the two DNA stocks, and the supernatant was used to determine the analytical sensitivity of TgsGP LAMP, TgsGP PCR (41), and nested TgsGP PCR (30) . The LAMP test was carried out under optimized conditions, and the PCR tests followed the respective published procedures. The resulting LAMP and PCR products were electrophoresed in a 2.0% Tris-acetate-EDTA (TAE) agarose gel stained with SYBR safe DNA gel stain (Invitrogen, Victoria, Australia). The gel images were documented using the Gel-Doc-XR system (Bio-Rad Laboratories).
RESULTS
Optimum conditions for TgsGP LAMP. The TgsGP primers chosen (Table 3 ) target a 220-bp section of TgsGP sequence that is between the specific sections amplified by the TgsGP PCR test (41) . Surprisingly, 3 of the 5 LAMP primer sets amplified T. b. brucei isolates B8/18 from Nigeria and TSW187/ 78E from Ivory Coast, raising the question of the specificity of the T. b. gambiense 3Ј end. A fourth primer set had a detection limit of 10 3 trypanosomes/ml, while the TgsGP primer set for this study showed a detection limit of 10 2 trypanosomes/ml using the 10-fold serial dilution of isolate PT41. The Taguchi method determined the final/optimal FIP and BIP primer concentrations at 40 pmol of each, 3 mM for each deoxynucleoside triphosphate, 1.2 M betaine, and 4 mM extra magnesium sulfate. The concentrations of other reagents were as previously reported (36) . The optimum temperature for TgsGP LAMP was determined to be 62°C, and 35 min was the assay cutoff point.
TgsGP-LAMP product. Positive LAMP reactions showed exponential amplification curves, as visualized in the real-time PCR machine. The advantage of optimization was demonstrated by the reduction in the cycle threshold (C T ) value by an average of 5 cycles for all 10-fold serial dilutions (Fig. 1A) and a 10-fold increase in sensitivity. T. b. gambiense isolates from different geographical regions showed identical melting curves, with a melting temperature (T m ) of 87°C (Fig. 1A) , suggesting amplicons with similar sequences. The positive LAMP products showed the predicted ladderlike pattern on the agarose gel, indicating the formation of stem-loops with inverted repeats (Fig. 1B) . Further addition of a 1/10 dilution of SYBR green I showed a green color with positive reactions and orange with negative reactions (Fig. 1C) . Sequencing of the uppermost LAMP band (Fig. 1B) revealed the predicted sequence from the F2-to-B2 primer region flanked by sequences from regions F1 and B1c on the 3Ј and 5Ј ends (Fig. 2) .
PCR and LAMP sensitivities. The PCR results are shown in Tables 1 and 2 . The positive samples showed the predicted ϳ308-bp amplicon using TgsGP PCR and an ϳ270-bp amplicon using nested TgsGP PCR. The analytical sensitivity was equivalent to 10 3 trypanosomes/ml and 10 trypanosomes/ml for the classical and nested TgsGP PCRs, respectively ( Table 4) . The TgsGP LAMP showed a detection limit of approximately 10 trypanosomes/ml of 10-fold serial dilutions of T. b. gambiense PT41 and approximately 1 trypanosome/ml when supernatant prepared from mouse blood was used ( Table 4 ). The TgsGP LAMP sensitivity results were identical when either a Rotorgene 6000 thermocycler or a water bath was used as a source of heat. The LAMP assay was specific, and no crossreactivity was recorded with nontarget DNA (Table 1) .
Results for clinical samples. Results for various clinical samples from patients diagnosed with T. b. gambiense are shown in Table 2 . After eliminating the use of direct buffy coat (RPH bc ) and bone marrow aspirate (RPH bma ) samples where inhibition of the LAMP reaction was expected, the highly sensitive RIME LAMP detected 12/18 samples and the TgsGP LAMP assay detected 9/18 and 9/12 of the RIME LAMP-positive samples. Analysis of various sample formats from single and different patients using LAMP tests and Trypanozoon-specific PCR (29) showed better results with BMA and CSF than with blood ( Table 2) . 
DISCUSSION
Case detection, followed by successful treatment, is a prerequisite for prevention and control of Gambian HAT. This strategy has faced significant problems due to a lack of sensitive diagnostic tests. Moreover, the diagnosis and staging of T. b. gambiense disease remains challenging, because the clinical features of the disease are not specific (4, 20) . Therefore, research into the advancement of HAT diagnostic capabilities is still a priority. In this study, we have demonstrated specific amplification of T. b. gambiense DNA using a LAMP assay based on the TgsGP gene. The test is rapid, and amplification is achieved within 30 min using a real-time PCR machine at 62°C (Fig. 1A) and 40 min using a normal water bath and detecting the product through addition of fluorescent dye (Fig.  1C) . Although the use of a normal water bath simplifies the need for instrumentation, nevertheless, the requirement for power to heat the water is still a drawback. As such, other sources of heat, like packaged exothermic reactions, need to be explored. The TgsGP LAMP was specific and exhibited analytical sensitivity of ϳ10 trypanosomes/ml, which was equal to that of nested TgsGP PCR (Table 4) ; therefore, to date, TgsGP LAMP is the most sensitive single-step T. b. gambiense DNA-based test. However, as was observed with the serum resistance-associated (SRA) gene-based LAMP tests (35) , this specific laboratory-based sensitivity may not be reproducible under field conditions, and thus, rigorous TgsGP LAMP field evaluations will be the next most important step.
The potential usefulness of TgsGP LAMP as a point-of-care test is demonstrated by the ability of the new assay to amplify target DNA from various templates, such as native CSF and double-centrifuged supernatant (Table 2 ). More promising is the ability of TgsGP LAMP to achieve 10-fold-higher sensitivity from supernatant than from DNA prepared from the same sample, meaning that DNA extraction may not be necessary, which would also shorten the assay time. Similar results were recorded with RIME LAMP (34) . It is suggested that a significant amount of parasite DNA is lost during the extraction process, resulting in a lower detection limit when purified DNA is used as a template. However, before supernatant can be relied upon as a template for LAMP reactions, protocols for template purification and buffers that stabilize DNA in the supernatant need to be developed. This is because false-positive results (albeit rare) have previously been recorded with single centrifuged supernatants (33) , while an initially positive supernatant turns negative after 3 weeks of storage at Ϫ20°C, suggesting degradation of the target DNA (Z. K. Njiru, unpublished data).
A field-based TgsGP LAMP will require a detection format(s) that is cheap and simple and that allows visual inspection of the results. However, most of these formats do not offer the option of confirming the LAMP product. Therefore, it is imperative to ensure that the developed test is specific and amplifies the predicted target. False positives in LAMP reactions are not necessarily absent and can result from amplicon contamination, unprocessed templates, the quality and composition of primers (poorly designed primers, frequent freezing and thawing, and AT-rich primers). In this study, the amplification of the target sequence from purified DNA, supernatant, and native CSF was unequivocally confirmed through postamplification acquisition of the melting curves, which showed a consistent T m of ϳ87°C (Fig. 1A) , indicating similar sequences, and through sequencing of the uppermost LAMP band (Fig.  1C) , which showed the predicted target sequence (Fig. 2) . Therefore, the use of nonspecific dye in this study, supported by both positive and negative controls, increases our confidence.
FIG. 2.
Representative sequence obtained after cloning and sequencing of the uppermost bands from the TgsGP LAMP product. The sequence was identical to the expected target sequence of 195 bp (15 bp from F2 to B2, plus F1c, 20 bp, and B1, 22 bp). An identical sequence was obtained for the LAMP product acquired using the native CSF sample RPH9 (Table 3) . Shading is used to distinguish the primer sections. Note that the sequence differs depending on the band sequenced and the inner primer initiating the reaction. F, forward primers; B, backward primers; L, loop primers; C, complementary sequence. 
a Supernatant was prepared from mouse blood mixed with trypanosomes. b DNA from T. b. gambiense PT41 and from mouse blood prepared from 1.0 ϫ 10 6 trypanosomes/ml. c 10
Ϫ1
, ϳ1.0 ϫ 10 5 trypanosomes/ml; 10
Ϫ2
, ϳ1.0 ϫ 10 4 trypanosomes/ml; 10
Ϫ8
, ϳ0.01 trypanosomes/ml; neat, approximately 100 ng; ϩ, positive; Ϫ, negative.
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Early and accurate diagnosis of T. b. gambiense is essential in reducing the risk of progression of infection to the late stage, which is difficult and dangerous to treat compared to the early stage (22) . The challenge of T. b. gambiense diagnosis is well demonstrated in this study by low detection of parasite DNA in the most used patient sample, blood (samples OM and RPH1 to -4), using the available DNA detection tests. TgsGP LAMP detected 75% of the RIME LAMP-positive samples ( Table 2 ). The sensitivity of the RIME LAMP is expected to be higher, since the test is a based on a multicopy gene (500 copies per haploid genome) (3) while TgsGP is based on a low-copynumber target. Unfortunately, RIME LAMP cannot differentiate between T. b. gambiense and T. b. rhodesiense, which is crucial, since the two parasites have different treatment regimens. Moreover, in East Africa, the introduction of T. b. rhodesiense into the T. b. gambiense region is certain to occur due to the closeness of the two disease foci and the continuous movement of livestock. We initially designed a test specific for T. b. rhodesiense (36) , and the TgsGP LAMP designed in this study has the potential to contribute to T. b. gambiense diagnosis.
Our results show that the CSF is a better source of template for diagnosis of stage II diseases than blood. This is supported by the analysis of varied samples (native, supernatant, and DNA) from different patients ( Table 2 ). Similar superior detection has been recorded using CSF PCR (16) . Since the presence of T. b. gambiense had been confirmed in all the patients (34), it is suggested that the levels of parasitemia in the blood were too low and/or a great deal of DNA was lost during the extraction process. This concept is supported by similar low detection results observed using T. brucei (TBR) PCR and RIME LAMP tests specific for the multicopy and highly sensitive subgenus Trypanozoon (34) . Further studies need to be carried out using only confirmed stage 1 patients to elucidate the sensitivity of the TgsGP LAMP test versus other molecular tests.
The application of nucleic acid-based tests in the diagnosis of Gambian sleeping sickness has been limited in the areas of endemicity, since most of the tests still require standardization and clinical validation (8) . Furthermore, they are laborious and expensive and require elaborate visualization methods. In this study, the potential usefulness of the TgsGP LAMP test was demonstrated by its ease of applicability, rapidity, and higher sensitivity than the classical PCR targeting the same gene (Table 4). Moreover the ability of the test to detect parasite DNA in CSF is expected to contribute to diagnosis of the late-stage disease. Indeed, the staging of the late-stage HAT by the presence of trypanosomes in CSF and/or an elevated white blood cell (WBC) count above 5 cells/cm 2 is not reliable (11,) nor are the existing CSF parasite detection methods sufficiently sensitive (23) . However, a positive LAMP CSF result needs to be interpreted with caution, since it may not necessarily indicate living trypanosomes in the CSF but rather their DNA. It has been previously suggested that the presence of DNA in the CSF may result from leakage of circulating DNA in the blood through the blood brain barrier, or DNA can originate from nonsurviving parasites as a consequence of the suboptimal CSF survival environment (38) . The issue of DNA rather than live parasites complicating interpretation should be studied using a primate model for HAT, which will elucidate the role of TgsGP LAMP and other HAT LAMP tests in determining cure. For now, LAMP results need to be interpreted in comparison to those of other tests and/or clinical symptoms.
Since the TgsGP LAMP test designed in this study is based on the TgsGP gene, it does not detect T. b. gambiense group 2, like TgsGP PCR. However, the vast majority of T. b. gambiense patients across all foci have group 1 infections, and the overall percentage of isolates from group 2 is so low as to be negligible, and only a few of them exist in laboratories. It is difficult to get a specific marker for group 2, since it is heterogeneous and genetically indistinguishable from T. brucei brucei. The lack of a universal diagnostic marker for T. b. gambiense and the reduced detection in blood affirms the need to continue evaluating other biomarkers. In practice, if the TgsGP LAMP test (CSF) is to be introduced, it may need to be combined with a test like CATT (blood) until the issues of LAMP sensitivity using blood are resolved. The TgsGP LAMP test developed here must be evaluated to investigate whether it can be used as a xenomonitoring tool and in detection of the T. b. gambiense parasite in suspected reservoir hosts (32) .
The elimination of HAT as a public health problem in subSaharan Africa is a realistic objective. However, this will rely in part on the availability of affordable, sensitive, and field-applicable diagnostic technologies. In summary, this work shows (i) that the TgsGP LAMP is more sensitive than TgsGP PCR, (ii) that the use of supernatant increases the test sensitivity by 10-fold, (iii) that the use of CSF increases the chance of parasite DNA detection for stage II disease compared to blood (or its buffy coat from the same patient), and (iv) that the test is robust and amplification can be achieved using a normal water bath without compromising the test sensitivity. The LAMP test designed in this work and other recent technologies, such as the dipstick (10) and a sensitive semiquantitative card agglutination test, Latex/IgM (21), offer new prospects for improved detection of Gambian HAT. The next major step for the TgsGP LAMP test will be focused on field evaluation with the aim of generating data for development of a kit.
